Amgen Completes Acquisition of Abgenix
Acquisition Provides Amgen with Full Ownership of Panitumumab and Eliminates a Denosumab Royalty
05-Apr-2006 -
Amgen announced the completion of the acquisition of Abgenix, Inc., a company specializing in the discovery, development and manufacture of human therapeutic antibodies. Final regulatory approvals were received in January and Abgenix stockholders overwhelmingly approved Amgen's acquisition of the ...
Amgen
oncology
regulatory approval
+1